BGLC (BioNexus Gene Lab) Interest Expense : $-0.02 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is BioNexus Gene Lab Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BioNexus Gene Lab's interest expense for the three months ended in Dec. 2024 was $ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.02 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BioNexus Gene Lab's Operating Income for the three months ended in Dec. 2024 was $ -0.80 Mil. BioNexus Gene Lab's Interest Expense for the three months ended in Dec. 2024 was $ -0.01 Mil. BioNexus Gene Lab did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioNexus Gene Lab Interest Expense Historical Data

The historical data trend for BioNexus Gene Lab's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNexus Gene Lab Interest Expense Chart

BioNexus Gene Lab Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-0.01

-0.02

BioNexus Gene Lab Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-	-0.01	-	-0.01	-0.01

BioNexus Gene Lab Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02 Mil.

BioNexus Gene Lab (NAS:BGLC) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioNexus Gene Lab's Interest Expense for the three months ended in Dec. 2024 was $-0.01 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-0.80 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $0.16 Mil.

BioNexus Gene Lab's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

BioNexus Gene Lab did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

BioNexus Gene Lab Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioNexus Gene Lab Corp (NAS:BGLC) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

BGLC:USA

Address

No. 8 Jalan Kerinchi, The Vertical Business Suite II, Unit 02, Level 10, Tower B, Avenue 3, Bangar South, Kuala Lumpur, SGR, MYS, 59200

Website

https://www.bionexusgenelab.com

BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.

Executives

Chak Hua Yew	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yeat Min Fong	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Teng Fook Fong	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chee Keong Yap	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Boon Teong Teoh	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Yee Meng Wong	director, officer: President	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Wei Li Leong	officer: Chief Financial Officer	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chai Ping Lin	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Tai Tan Liong	director, officer: Chief Operating Officer	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Sook Keng Yeoh	director, officer: Chief Executive Officer	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200